Rabbit Recombinant Monoclonal TPD52 antibody - conjugated to PE.
pH: 7.4
Preservative: 0.02% Sodium azide
Constituents: 98% PBS, 1% BSA
| Application | Reactivity | Dilution info | Notes |
|---|---|---|---|
Application Antibody Labelling | Reactivity Expected | Dilution info - | Notes - |
Application Target Binding Affinity | Reactivity Expected | Dilution info - | Notes - |
Select an associated product type
Tumor protein D52, Protein N8, TPD52
Rabbit Recombinant Monoclonal TPD52 antibody - conjugated to PE.
pH: 7.4
Preservative: 0.02% Sodium azide
Constituents: 98% PBS, 1% BSA
Based on immunogen sequence analysis, ab182578 recognizes 4 isoforms with the predicted MWs of 24KDa, 20KDa, 26 KDa and 22KDa, respectively.
This conjugated primary antibody is “made to order” and it is released using a quantitative quality control method that ensures binding affinity and labelling efficiency of the conjugate. Via leveraging the power of the Lightning-Link® conjugation technology, Abcam will deliver highly consistent recombinant conjugates in <2 weeks, giving you access to an ever growing portfolio of antibody-label combinations.
For suitable applications and species reactivity, please refer to the unconjugated version of this clone.
This product is FOR RESEARCH USE ONLY. For commercial use, please contact partnerships@abcam.com.
This conjugated primary antibody is released using a quantitative quality control method that evaluates binding affinity post-conjugation and efficiency of antibody labeling.
For suitable applications and species reactivity, please refer to the unconjugated version of this clone. This conjugated antibody is eligible for the Abcam trial program.
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
This product is a recombinant monoclonal antibody, which offers several advantages including:
For more information, read more on recombinant antibodies.
The Tumor Protein D52 (TPD52) is a 224 amino acid protein also known as PrLZ or D52-like protein 1 with a mass of approximately 23 kDa. TPD52 features prominently in the regulation of cell proliferation and vesicle trafficking. It is expressed in a wide range of tissues with significant expression levels in the pancreas prostate and various cancers. TPD52 associates with other members of the D52 family proteins forming homo- or heterodimers that play a part in its function.
TPD52 is involved in cellular processes like growth apoptosis and exocytosis. It often forms part of protein complexes assisting in intracellular signaling pathways and vesicular transport mechanisms. The ability of TPD52 to interface with other proteins such as 14-3-3 or annexins provides it with diverse functionality. Moreover its involvement in regulating secretory pathways underlines its importance in different cell types particularly those with high secretion activity.
TPD52 integrates into the MAPK and calcium signaling pathways. The MAPK pathway which includes key proteins like ERK1/2 involves TPD52 in processes affecting cell growth and differentiation. TPD52 can act upstream or downstream of MAPK components indicating its dynamic role in the pathway. Similarly in calcium signaling TPD52 interacts with annexins which position it within calcium-dependent exocytotic events and cellular responses dependent on Ca2+ dynamics.
TPD52 shows an association with cancers such as prostate and breast cancer. In breast cancer its overexpression correlates with rapid tumor growth and decreased patient survival rates. TPD52's link to the protein AKT suggests a role in oncogenic pathways where AKT promotes cell survival and growth. Similarly in prostate cancer altered expression levels of TPD52 may enhance tumorigenic potential and aggressiveness establishing TPD52 as a potential therapeutic target for cancer treatments.
We have tested this species and application combination and it works. It is covered by our product promise.
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com